Liraglutide (Saxenda) is an older daily injectable GLP-1 that produces moderate weight loss (~8%) and is also FDA-approved for pediatric patients aged 12 and older
Not all hair loss is attributable to telogen effluvium, and a thorough clinical assessment is important to exclude other underlying conditions
Request for data access can be submitted via Vivli, and expected time for response is around 60 days
Side effects during the first week tend to be mild but present
If you are interested in specific compound blends, we have detailed guides on tirzepatide with B12 , tirzepatide niacinamide , tirzepatide glycine , tirzepatide glycine B12 blends , tirzepatide methylcobalamin , tirzepatide with B6 , tirzepatide hydroxocobalamin , and tirzepatide levocarnitine blends